Cannabidiol (CBD), a key compound in cannabis, increases cerebral blood flow (CBF) in regions of the brain linked to memory processing, suggests a recent study in the Journal of Psychopharmacology. The results suggest the potential use of CBD for disorders associated with altered memory processing including post-traumatic stress disorder (PTSD), schizophrenia, depression, and Alzheimer’s disease.
CBD is being investigated as a potential treatment for several disorders of which many are characterized by altered memory processing. However, there is no clarity on the mechanisms underlying these effects. Michael A P Bloomfield, University College London, London, UK, and colleagues investigated 1) how CBD influences cerebral blood flow (CBF) in regions involved in memory processing, and 2) if the effects of CBD on CBF were associated with differences in working and episodic memory task performance.
Sativa Group Plc (NEX:SATI) is the UK’s leading quoted CBD Wellness and medicinal cannabis group with five operating subsidiaries. Goodbody Botanicals provides CBD products online and to retail markets including pharmacies, wellness stores and grocers. Goodbody Wellness is a high-street retail brand with dedicated CBD Wellness stores providing a premium shopping experience to consumers. Tessellate Collective is a direct-selling network marketing platform servicing consumers at home. Phytovista laboratories provides independent testing of CBD products to both external customers and fellow Group businesses. Sativa Grow holds a Controlled Drug licence and cultivates cannabis plants to fulfill its partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.